ArteraAI

ArteraAI is happy to announce that the #ArteraAI Prostate Test is the First-and-Only Predictive Test for Therapy Personalization in the 2024 National Comprehensive Cancer Network? (NCCN?) Guidelines? for Prostate Cancer. Our test is the only test included for its predictive performance, and also the first AI-enabled predictive and #prognostic test to be recommended in the guidelines for localized #prostatecancer. This is an exciting step forward for ArteraAI. As Andre Esteva, PhD, CEO and Co-Founder of ArteraAI said, “This significant milestone not only celebrates ArteraAI's success but also paves the way for the integration of AI-enabled solutions into clinical practice, illustrating their potential to enhance personalized patient care.” Read the announcement here:

Howdy Dallas! Excited to be attending #SUO2024, where there'll be a lively discussion of issues among members of the urologic oncology community. Be sure to stop by #ArteraAI to meet with Pete Simchera, Seth Schulman, Christopher Tweed, PharmD, BCOP, Tim Showalter, and Zach Wilczynski to learn more about how the #ArteraAI Prostate Test is helping patients with localized #prostatecancer.

ICYMI: Dr. Jonathan Tward of University of Utah Health recently published in JCO Precision Oncology a comparison of the risk stratification performance between #NCCN clinical variables and #MMAI. Highlights include how the #ArteraAI model reclassified 42% of patients into different risk groups, mostly down reclassification. To read the full publication: https://lnkd.in/ecuePUwi

In a new video with UroToday + GU OncToday, Dr. Phuoc T. Tran, Professor and Vice Chair of Research at the University of Maryland School of Medicine Greenebaum Comprehensive Cancer Center, discusses new data validating the ability of Artera's #biomarker to help inform treatment decisions around metastasis-directed therapy (MDT) for patients with oligometastatic castration-sensitive prostate cancer, or omCSPC - an early stage of metastatic #prostatecancer, recently presented at the 66th #ASTRO Annual Meeting in Washington, DC: https://heyor.ca/wqLDoG

We're proud to announce the first patient enrollment in the prospective HypoPro/HypoElect Phase II trials, using #ArteraAI MMAI to risk stratify patients with high-risk #prostatecancer and deliver precise treatments. Under the guidance of the #principalinvestigators, Dr. Constantinos Zamboglou, MHBA and Dr. Iosif Strouthos from the German Oncology Center, these trials represent an innovative approach by combining precision radiotherapy techniques and systemic therapy, tailored by AI to enhance #patientoutcomes.

What an amazing few days at #LUGPA2024! We enjoyed meeting with a ton of #urologists and sharing how the #ArteraAI Prostate Test can guide personalized treatment decision-making for patients. Looking forward to continuing the conversations with all our customers and partners at the #LUGPA Global Prostate Cancer Congress in 2025.

How can the #ArteraAI Prostate Test improve decision-making for low-risk patients? Artera CEO & Co-Founder Andre Esteva, PhD, joins Dana-Farber Cancer Institute's Alicia Morgans to discuss how the ArteraAI #ProstateTest can help clinicians decide between #activesurveillance and definitive treatment by assessing the risk of adverse pathology at #prostatectomy, and how Artera's partnership with PathNet is enabling faster delivery of results by integrating AI analysis with pathology reports, in a new video with UroToday + GU OncToday:

One of our core tenets is putting the Artera #MMAI models through extensive validation. We are proud to partner with Hackensack Meridian Health and Nitin Yerram, M.D. to investigate new clinical endpoints to better guide treatment decisions after #prostatectomy. https://heyor.ca/Spv4Mq #precisionmedicine #prostatecancer #AI #personalizedcancercare

The #ArteraAI team was thrilled to be at the Prostate Cancer Foundation #PCFRetreat2024, the foremost scientific conference in the world on the biology and treatment of #prostatecancer. Our own Emmalyn Chen, Director of Research & Publications, presented a poster with Dr. William Chen anchoring the AI model to known prostate tumor biology (e.g., AR, PSMA, CD20).

In the latest episode of Exploring Artificial Intelligence in Oncology, Dr. Waqas Haque , Oncology Fellow at the University of Chicago, sat down with Dr. Trevor Royce MD MPH FASCO, Senior Medical Director of Artera, to discuss how the #ArteraAI Prostate Test can help make personalized treatment decisions in #prostatecancer, as well as Artera's research expansion - a new #breastcancer prognostic model for early-stage breast cancer, recently presented at #ASCO24: https://lnkd.in/e87zmXBC